Why is upatinib not recommended? What conditions does it apply to and what taboos do special groups of people need to pay special attention to?

Upadacitinib is an oral Janus kinase (JAK) inhibitor, mainly used to treat immune system-mediated diseases such as rheumatoid arthritis (RA), atopic dermatitis, and ulcerative colitis. Although it has significant efficacy in treating immune system diseases, its use requires special caution, especially in some specific conditions and special populations. The following are the reasons why the use of upadatinib is not recommended, as well as its applicable conditions and contraindications.

Upatinib, as a JAK inhibitor, regulates the immune response and reduces inflammation by inhibiting the JAK-STAT signaling pathway. However, this also means that it may have a strong suppressive effect on the immune system, leading to reduced immunity and an increased risk of infection. Upadatinib may cause upper respiratory tract infections, pneumonia, tuberculosis and other serious infections, especially in patients with immunosuppressed background. In addition, long-term use of JAK inhibitors may also lead to abnormalities in the blood system, such as anemia, leukopenia, thrombocytopenia, etc. Therefore, patients need to strictly follow the doctor’s instructions when using upadacitinib and avoid using it in an infectious state.

Upadatinib is primarily indicated for adults with rheumatoid arthritis who have failed to respond to conventional disease-modifying antirheumatic drugs (DMARDs ) or other treatments. In addition, it is also indicated for patients with moderate to severe atopic dermatitis, especially those who have not responded to other treatments. Upadatinib is also used in patients with ulcerative colitis who have not been able to control their disease with other treatments. However, patients using upapatinib must undergo detailed evaluation to confirm that the indications are consistent with the treatment plan, and only then can they use it after eliminating relevant contraindications.

For special populations, the use of upadatinib requires extra caution. First, pregnant and breastfeeding women should avoid upadacitinib because the drug's safety in these groups has not been fully established. Secondly, patients with severe hepatic and renal insufficiency should also avoid the use of upadatinib, as its metabolism in these patients may be affected, leading to accumulation of the drug and increasing the risk of side effects. In addition, the elderly and frail, especially those with cardiovascular disease, diabetes or other chronic diseases, require strict monitoring when using upadacitinib, as the drug may increase the risk of complications in these patients.

Upadatinib is contraindicated in patients with severe active infection, tuberculosis infection, or immunocompromised patients because its immunosuppressive effects may worsen infection. Caution is also required when using upadatinib in patients with a history of malignancy. During use, patients need to undergo regular blood tests, monitor liver and kidney function, and infection symptoms. If obvious signs of infection occur, such as fever, cough, fatigue, etc., the patient should stop taking the medicine immediately and seek medical treatment. In addition, upadatinib also requires regular cardiovascular monitoring, especially in patients with existing cardiovascular disease or hypertension.

Reference materials:https://www.rinvoq.com/